Evidence map›Paper›PMID 39624447›Full record

ArticleAsia Pacific allergy2024

Evaluation of the protocol for rush subcutaneous immunotherapy with birch pollen extract.

Masaaki Hamada, Masakazu Kagawa, Ichiro Tanaka

Abstract read
In one paragraph

Article in Asia Pacific allergy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Masaaki HamadaDepartment of Pediatrics, Yao Municipal Hospital, Yao, Osaka, Japan.ORCID https://orcid.org/0000-0002-1369-4713
Masakazu KagawaDepartment of Clinical Research Center, Yao Municipal Hospital, Yao, Osaka, Japan.ORCID https://orcid.org/0000-0003-3436-8842
Ichiro TanakaDepartment of Pediatrics, Yao Municipal Hospital, Yao, Osaka, Japan.ORCID https://orcid.org/0000-0001-6947-0068

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported the effectiveness of rush subcutaneous immunotherapy with birch pollen extract (Birch rSCIT) for pollen-food allergy syndrome (PFAS) and the high rate of systemic reactions (SR) during the rapid escalation phase. In this study, we examined whether modifying the dose escalation protocol of Birch rSCIT would reduce SR and maintain therapeutic effects. Birch rSCIT was introduced in 20 patients with PFAS who experienced systemic symptoms upon ingestion of soybeans. Birch rSCIT was implemented using 3 protocols: 2 protocols (nonstep-up group) increased the target dose to more than 1:2 × 10

Indexed as

Allergen immunotherapybirch pollenpollen-food allergy syndromerush subcutaneous immunotherapysoybean allergy

Identifiers

PMID39624447
PMCPMC11608609

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.